Tıp Fakültesi / Faculty of Medicine
Permanent URI for this collectionhttps://hdl.handle.net/11727/1403
Browse
2 results
Search Results
Item Chronic Renal Disease and hypertension are Significant Predictors of Severe Coronary Artery Disease Among Patients Presenting to Emergency Department with Atrial Fibrillation and Undergoing Coronary Angiography for Presumed Acute Coronary Syndrome(2017) Ciftci, Orcun; Karacaglar, Emir; Yilmaz, Keremcan; Muderssioglu, Ibrahim Haldun; 0000-0002-2538-1642; 0000-0001-8926-9142; ABI-6723-2020; W-5233-2018Item Platelet Membrane Gamma-Glutamyl Transferase-Specific Activity and the Clinical Course of Acute Coronary Syndrome(2019) Demirtas, Koray; Yayla, Cagri; Sade, Leyla Elif; Yildirir, Aylin; Ozin, Mehmet Bulent; Haberal, Aysegul; Muderrisoglu, Ibrahim Haldun; 0000-0001-8750-5287; 29996664; A-4947-2018gamma-Glutamyl transferase (GGT) participates in oxidative and inflammatory reactions inside the atheroma plaque and platelets. We evaluated whether platelet membrane gamma-glutamyl transferase (Plt-GGT) activity is a predictor of major adverse cardiac events (MACEs) during 3 months follow-up of patients with acute coronary syndrome (ACS; MACE-3M). We included 105 patients who were hospitalized consecutively with the diagnosis of ACS. Patients with an MACE-3M were older, more likely to have hypertension, hyperlipidemia, family history of coronary artery disease(CAD), thrombolysis in myocardial infarction (TIMI) risk score >4, higher Plt-GGT and serum GGT activities, serum C-reactive protein level, and lower left ventricular ejection fraction (LVEF) when compared to those without MACE-3M (all P values <=.05). By receiver-operator characteristic (ROC) curve analysis, 265 mU/mg for Plt-GGT, 30 U/L for serum GGT, and 45% for LVEF were determined as cutoff values to discriminate MACEs. Platelet GGT activity >265 mU/mg, TIMI risk score >4, and family history of CAD were independent predictors of MACE-3M (all P values <.05). Platelet GGT activity was as an independent predictor for MACEs in patients with ACS during the 3 months follow-up.